Work

Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now?

Year: 2017

Type: article

Abstract: Glaucoma is the second most common cause of blindness, affecting 70∼80 million people around the world. The death of retinal ganglion cells (RGCs) is the main cause of blindness related to this disease. Current therapies do not provide enough protection and regeneration of RGCs. A novel opportunity for treatment of glaucoma is application of technologies related to stem cell and gene therapy. In this perspective we will thus focus on emerging approaches to glaucoma treatment including stem cells and gene therapy.

Source: International Journal of Stem Cells

DOI: 10.15283/ijsc17029

Authors: Karim Daliri, Alexander V. Ljubimov, Seyedhossein Hekmatimoghaddam

Institutions: Shiraz University, Shiraz University of Medical Sciences, Hertie Institute for Clinical Brain Research, University of Tübingen, Cedars-Sinai Medical Center, University of California, Los Angeles, Shahid Sadoughi University of Medical Sciences and Health Services

Language: English

Topic: Glaucoma and retinal disorders

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W2747223100

FWCI: 3.573

Cites: 70

Cited by: 34

Related to: 10